🚚 Free Tracked 24 on all pens · other orders free over £50, otherwise £5.99 🖊️ Peptide Pens → 🖊️ Retatrutide Pens: 20mg £124.99 · 40mg £159.99 → 🎬 View Peptide Videos → 🔬 New: Senolytics & Longevity Research. Explore the science → 👤 Members save 10% on eligible products. Join free → 🚚 Free Tracked 24 on all pens · other orders free over £50, otherwise £5.99 🖊️ Peptide Pens → 🖊️ Retatrutide Pens: 20mg £124.99 · 40mg £159.99 → 🎬 View Peptide Videos → 🔬 New: Senolytics & Longevity Research. Explore the science → 👤 Members save 10% on eligible products. Join free → 🚚 Free Tracked 24 on all pens · other orders free over £50, otherwise £5.99 🖊️ Peptide Pens → 🖊️ Retatrutide Pens: 20mg £124.99 · 40mg £159.99 → 🎬 View Peptide Videos → 🔬 New: Senolytics & Longevity Research. Explore the science → 👤 Members save 10% on eligible products. Join free →

What Lilly Reported on Retatrutide at Its November 2026 Conference

What Lilly Reported on Retatrutide at Its November 2026 Conference

By the Corex Vitality™ Research Team · 15 November 2026 · Sources listed at the end

Quick summary

  • On 14 November 2026, Eli Lilly and Company issued a press release about data it would present at Lilly’s November 2026 conference presentation, held in Washington, D.C. from 14 to 17 November.
  • Lilly describes retatrutide as an investigational triple receptor agonist: one molecule designed to act at the GIP, GLP-1 and glucagon receptors. It is in Phase 3 studies.
  • Lilly reported Phase 3 figures from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 for two trial measures: the apnea-hypopnea index (AHI) and the WOMAC pain subscale.
  • In the same release, Lilly said retatrutide “is an investigational molecule that cannot be legally sold or marketed for human use.”

This article sets out only the retatrutide Phase 3 figures Lilly gave in its 14 November 2026 press release. It does not interpret them as medical advice, and it does not describe any use of the compound.

What retatrutide is

Retatrutide (development code LY3437943) is a synthetic peptide. Lilly describes it as an investigational triple hormone receptor agonist: one molecule designed to activate the receptors for GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon.

Our explainer on GLP-1, GIP and glucagon receptor peptides covers how these receptors are studied in the lab. A separate page sets out the structure of retatrutide.

Lilly’s release states that retatrutide “is an investigational molecule that cannot be legally sold or marketed for human use.”

What Lilly reported for sleep apnoea (TRIUMPH-1 and TRIUMPH-2)

Lilly said an oral session on 15 November 2026 would present Phase 3 results for retatrutide. AHI means the apnea-hypopnea index, a count of breathing disruptions during sleep, given as events per hour.

In TRIUMPH-1 (ClinicalTrials.gov NCT05929066), Lilly reported that retatrutide reduced breathing disruptions during sleep, as measured by AHI, by up to an average of 36.1 events per hour (60.6%) at 80 weeks in the TRIUMPH-1 trial population described in Lilly’s release, which included moderate-to-severe obstructive sleep apnoea (OSA).

In TRIUMPH-2 (NCT05929079), Lilly reported that retatrutide reduced AHI by up to an average of 28.4 events per hour (48.1%) at 80 weeks in the TRIUMPH-2 trial population described in Lilly’s release, which also included moderate-to-severe OSA.

What Lilly reported for knee osteoarthritis (TRIUMPH-1 and TRIUMPH-4)

The same release gave figures on the WOMAC pain subscale (the Western Ontario and McMaster Universities Osteoarthritis Index).

In TRIUMPH-1, Lilly reported that retatrutide reduced knee osteoarthritis pain, as measured by the WOMAC pain subscale, by up to an average of 4.3 points (73.1%) at 80 weeks in the TRIUMPH-1 trial population described in Lilly’s release, which included knee osteoarthritis pain.

In TRIUMPH-4 (NCT05931367), Lilly reported that retatrutide reduced WOMAC pain by up to an average of 4.5 points (75.8%) at 68 weeks in the TRIUMPH-4 trial population described in Lilly’s release, which included knee osteoarthritis pain.

How to read these figures

These numbers come from Lilly’s press release, not from a full published paper cited in this article. They are company-reported “up to” averages. The release does not give the matching placebo figures in the same sentences. This article reports the figures as Lilly stated them. It does not present them as a reason to use retatrutide, and it offers no guidance on use in people or animals.

Lilly also presented other data at the same meeting, including Phase 2 results for EloraTZP and results for Zepbound (tirzepatide). Those programmes are not covered here.

For laboratories

Corex Vitality™ supplies retatrutide only as a research chemical for in-vitro laboratory work. You can view our retatrutide research peptide, a short research video, and the batch certificates on our verification page. UK search interest in the compound is covered in a separate article.

Sources

All Corex Vitality™ products are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. No information here describes use in humans or animals.

Cover of the free guide: How to read a COA

Free guide

How to read a COA

Get it by email, plus our research updates. No spam, unsubscribe any time.

We will email you to confirm first, then send the guide. We use your name and email only to send you these emails. Privacy policy. For laboratory research use only.

Listed on PepmarketVerified on PeptideReview